

PRIOR AUTHORIZATION REQUEST

Emflaza

Patient	Information	:			
Name:					
Membe	er ID:				
Addres	ss:				
City, St	tate, Zip:				
Date of	f Birth:				
Prescri	ber Informat	ion:			
Name:					
NPI:					
Phone	Number:				
Fax Nu					
Addres	is:				
	tate, Zip:				
	, l l				
	sted Medicat	ion			
Rx Name:					
Rx Strength					
Rx Quantity:					
	quency:				
Rx Rou					
	stration:				
Diagnosis and ICD Code:					
prescribe quantities Upon red	ed a medication is can be provide ceipt of the color of t	for your ed. Plea ompleted	efit requires that we review certain requests for coverage with the part patient that requires Prior Authorization before benefit coverage or consecutive the following questions then fax this form to the toll-free red form, prescription benefit coverage will be determined based on the that supporting clinical documentation is required.	overage of number lis on the pla	f additiona sted belov an's rule
1	Is the patien [If no, skip to		ntly receiving Emflaza/Deflazacort? ion 4]	Yes	No
2	Has the patient been receiving medication samples for the requested medication? [If yes, skip to question 4]			Yes	No
3	Has documentation been submitted to confirm that the patient has had a clinically significant response to therapy, as determined by the provider? ACTION REQUIRED: Submit supporting documentation. [No further questions.]			Yes	No
4	What is the	diagnos	sis or indication?		

PRIOR AUTHORIZATION REQUEST

	[] Duchenne Muscular Dystrophy (DMD) (If checked, go to 5)						
	[] Other (If checked, no further questions)						
5	What is the requested medication?						
	[] Deflazacort (generic) (If checked, go to 7)						
	[] Emflaza (brand) (If checked, go to 6)						
6	Has the patient had a trial and failure of the generic product, deflazacort? [If no, no further questions]	Yes	No				
7	Is the patient greater than or equal to 2 years of age? [If no, no further questions.]	Yes	No				
8	Is the requested medication being prescribed by or in consultation with a physician who specializes in the treatment of Duchenne Muscular Dystrophy (DMD) and/or neuromuscular disorders? [If no, no further questions.]	Yes	No				
9	Is documentation being provided to confirm that the patient has tried prednisone for GREATER THAN or EQUAL to 6 months? ACTION REQUIRED: Submit supporting documentation. [If yes, no further questions.]	Yes	No				
10	Is documentation being provided to confirm that, according to the prescriber, the patient has had a significant intolerable adverse effect (that is Cushingoid appearance, central [truncal] obesity, undesirable weight gain defined as a GREATER THAN or EQUAL TO 10% of body weight gain increase over a 6-month period, diabetes and/or hypertension that is difficult to manage according to the prescriber)? ACTION REQUIRED: Submit supporting documentation. [If yes, no further questions.]	Yes	No				
11	Is documentation being provided to confirm that, according to the prescriber, the patient has experienced a severe behavioral adverse effect while on prednisone therapy that has or would require a prednisone dose reduction? ACTION REQUIRED: Submit supporting documentation.	Yes	No				

Please document the diagnoses, symptoms, and/or any other information important to this review:



PRIOR AUTHORIZATION REQUEST

SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.